Accendra Health Completes P&HS Sale, Eyes Leaner Future
Event summary
- Accendra Health completed the sale of its Products & Healthcare Services (P&HS) business on December 31, 2025.
- Full-year 2025 revenue from continuing operations was $2.8 billion, up 3% year-over-year.
- The company reported a net loss from continuing operations of $102.7 million for the year.
- Accendra Health provided 2026 guidance with revenue expected between $2.55 billion and $2.65 billion.
The big picture
Accendra Health's divestiture of its P&HS business marks a significant strategic pivot, positioning the company to focus on its core home-based care solutions. This move aligns with broader industry trends toward specialization and operational efficiency in healthcare services. The completion of this sale and the ongoing separation from Owens & Minor will be critical in unlocking long-term value for stakeholders.
What we're watching
- Strategic Focus
- How Accendra Health's shift to a leaner structure will impact its ability to drive sustainable growth.
- Financial Performance
- Whether the company can meet its 2026 revenue and EBITDA guidance amid market uncertainties.
- Operational Efficiency
- The pace at which Accendra Health can improve cash flow generation through cost controls.
Related topics